| Literature DB >> 29193784 |
Antti M Haapalainen1,2, Minna K Karjalainen1,2, Ravindra Daddali1,2, Steffen Ohlmeier3, Julia Anttonen1,2, Tomi A Määttä1,2, Annamari Salminen1,2, Mari Mahlman1,2, Ulrich Bergmann3, Kaarin Mäkikallio1,4,5, Marja Ojaniemi1,2, Mikko Hallman1,2, Mika Rämet1,2,6.
Abstract
Understanding of timing of human parturition is incomplete. Therefore, we carried out proteomic analyses of full-term placentas from uncomplicated pregnancies to identify protein signatures associated with the onset of spontaneous delivery. We found quantitative associations of 10 proteins with spontaneous term birth, evident either in the basal or in the chorionic plates or in both. Additional 18 proteins were associated according to the location within placenta indicating local variations in protein amounts. Calcineurin-like phosphoesterase domain-containing 1 (CPPED1), a phosphatase previously suggested dephosphorylating AKT1/PKB, was one of the identified proteins. qRT-PCR revealed the mRNA level of CPPED1 was higher in elective caesarean deliveries than in spontaneous births, while immunohistochemistry showed CPPED1 in cytotrophoblasts, syncytiotrophoblasts and extravillous trophoblasts. Noteworthy, phosphorylation status of AKT1 did not differ between placentas from elective caesarean and spontaneous deliveries. Additionally, analyses of samples from infants indicated that single-nucleotide polymorphisms rs11643593 and rs8048866 of CPPED1 were associated with duration of term pregnancy. Finally, post-transcriptional silencing of CPPED1 in cultured HTR8/SVneo cells by siRNAs affected gene expression in pathways associated with inflammation and blood vessel development. We postulate that functions regulated by CPPED1 in trophoblasts at choriodecidual interphase have a role in the induction of term labour, but it may be independent of AKT1.Entities:
Keywords: CPPED1; genetics; placenta; proteomics; trophoblast
Mesh:
Substances:
Year: 2017 PMID: 29193784 PMCID: PMC5783879 DOI: 10.1111/jcmm.13402
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Birth phenotype‐ and location‐dependent changes in the human placenta proteome
| Spot | Protein | UniProt‐KB | Description | Theoretical pI/MW (kD) | Detected pI/MW (kD) | Ratio | |||
|---|---|---|---|---|---|---|---|---|---|
| E | Ba | ||||||||
| Ba | Ch | E | S | ||||||
| Elective (E) | |||||||||
| 46* | ACTB | P60709 | Actin, cytoplasmic 1 (fragment) | 5.29/41.7 (5.29/41.6) | 4.93 18 | 1,57 | (1,13) | 2,17 | (1,54) |
| 1 | A2M | P01023 | α‐2‐macroglobulin | 6.03/163.3 | 5.51 142 | −1,57 | (−1,45) | (1,12) | (1,22) |
| 2 | (5.98/160.8) | 5.54 142 | −1,62 | −1,59 | (1,09) | (1,13) | |||
| 3 | 5.57 142 | −1,55 | −1,67 | (−1,04) | (−1,11) | ||||
| 49 | B2M | P61769 | β‐2‐microglobulin | 6.06/13.7 (6.07/11.7) | 6.07 14 | (1,12) | 1,59 | (−1,45) | (−1,04) |
| 39 | CPPED1 | Q9BRF8 | Serine/threonine‐protein phosphatase (isoform 1) | 5.79/35.5 | 5.75 31 | −1,71 | −1,79 | (−1,14) | (−1,19) |
| 44 | CYB5A | P00167 | Cytochrome b5 (isoform 1 or 2) | 4.86/15.31 | 4.72 18 | −1,74 | −1,59 | (1,07) | (1,17) |
| 47 | HBG2 | P69892 | Haemoglobin subunit γ‐2 | 6.64/16.1 | 6.71 16 | −2,57 | −2,26 | (1,03) | (1,18) |
| 48 | (6.71/15.9) | 6.54 16 | −2,33 | −2,03 | (1,13) | (1,29) | |||
| 13 | KRT8 | P05787 | Keratin, type II cytoskeletal 8 (isoform 1 or 2) | 5.52/53.71 | 5.24 49 | (1,16) | 1,71 | (−1,14) | (1,30) |
| 14 | isoform 1 or 2 | 5.52/53.71 | 5.24 47 | (1,08) | 1,73 | (−1,29) | (1,24) | ||
| 15 | isoform 1 or 2 | 5.52/53.71 | 5.33 50 | (1,55) | 2,09 | (1,09) | (1,46) | ||
| 30* | fragment of isoform 1 or 2 | 5.52/53.7 | 4.79 37 | (1,81) | 2,39 | (1,59) | (2,09) | ||
| 31* | fragment of isoform 1 or 2 | 5.52/53.7 | 4.85 38 | (1,88) | 2,77 | (1,07) | (1,56) | ||
| 21 | KRT19 | P08727 | Keratin, type I cytoskeletal 19 | 5.05/44.2 | 4.85 41 | (−1,09) | 1,59 | (−1,15) | (1,48) |
| 29* | C‐terminal KRT19 fragment | 5.05/44.2 | 4.74 37 | (1,19) | 1,62 | (1,12) | (1,54) | ||
| 42 | PRDX2 | P32119 | Peroxiredoxin‐2 (isoform 1) | 5.66/21.9 (5.67/21.8) | 5.52 22 | −1,65 | (−1,49) | (1,10) | (1,21) |
| 22 | SERPINB2 | P05120 | Plasminogen activator inhibitor 2 | 5.46/46.6 | 5.51 42 | (−1,14) | −1,92 | (−1,18) | (−1,99) |
| Basal plate (Ba) | |||||||||
| 46* | ACTB | P60709 | Actin, cytoplasmic 1 (fragment) | 5.29/41.7 (5.29/41.6) | 4.93 18 | 1,57 | (1,13) | 2,17 | (1,54) |
| 38 | ANXA3 | P12429 | Annexin A3 | 5.62/36.4 (5.63/36.2) | 5.58 31 | (−1,35) | (1,39) | (1,52) | 2,83 |
| 45* | ANXA5 | P08758 | Annexin A5 (fragment) | 4.93/35.9 (4.93/35.8) | 4,83 18 | (1,39) | (−1,04) | 1,55 | (1,08) |
| 41 | APCS | P02743 | Serum amyloid P‐component | 6.10/25.4 (6.12/25.3) | 5.52 25 | (1,13) | (1,67) | (1,89) | 2,75 |
| 32 | CLU | P10909 | Clusterin (isoform 3 or fragments of isoforms 1,2,4, 5) | 5.88/52.51 | 4.76 36 | (1,13) | (1,65) | (1,98) | 2,87 |
| 33 | isoform 3 or fragments of isoforms 1,2,4, 5 | (5.89/50.11) | 4.82 35 | (1,13) | (1,57) | 2,16 | 2,98 | ||
| 34 | isoform 3 or fragments of isoforms 1,2,4, 5 | 4.88 34 | (−1,11) | (1,38) | 2,43 | 3,69 | |||
| 5 | EEF2 | P13639 | Elongation factor 2 | 6.41/95.3 (6.42/95.2) | 6.42 95 | (−1,02) | (−1,77) | (−1,34) | −2,32 |
| 23* | FGB | P02675 | Fibrinogen β (C‐terminal fragment in D dimer) | 8.54/55.9 | 5.51 38 | (1,43) | (1,57) | 2,25 | 2,45 |
| 24* | C‐terminal fragment in D dimer | (7.95/50.8) | 5.60 39 | (1,28) | (1,63) | 2,49 | 3,17 | ||
| 25* | C‐terminal fragment in D dimer | 5.71 39 | (1,16) | (1,56) | 2,54 | 3,42 | |||
| 26* | C‐terminal fragment in D dimer | 5.85 38 | (1,56) | (1,61) | 1,73 | (1,81) | |||
| 6 | FGG | P02679 | Fibrinogen γ (isoform gamma‐A or –B) | 5.37/51.5A | 5.46 94 | (2,55) | (1,68) | 2,07 | (1,36) |
| 7 | isoform γ‐A or –B | (5.24/48.5A) | 5.54 94 | (2,18) | (1,56) | 2,15 | (1,53) | ||
| 16 | isoform γ‐A or –B | 5.54 50 | (−1,13) | (1,16) | 1,58 | 2,05 | |||
| 43 | FTL | P02792 | Ferritin light chain | 5.50/20.0 (5.50/19.9) | 5.50 20 | (−1,03) | (−1,47) | (−1,97) | −2,75 |
| 4 | GSN | P06396 | Gelsolin (isoform 1) | 5.90/85.7 (5.72/82.9) | 5.82 95 | (−1,58) | (1,37) | (1,19) | 2,59 |
| 40 | HIBADH | P31937 | 3‐hydroxyisobutyrate dehydrogenase | 8.38/35.3 (5.54/31.5) | 5.62 29 | (−1,01) | (−1,42) | (−1,15) | −1,65 |
| 11 | HNRNPK | P61978 | Heterogeneous nuclear ribonucleoprotein K (isoform 1, 2 or 3) | 5.39/50.91 | 5.39 56 | (1,27) | (−1,74) | (−1,10) | −2,45 |
| 27 | HSD17B1 | P14061 | Estradiol 17‐β‐dehydrogenase 1 | 5.46/34.9 | 5.46 35 | (1,11) | (−1,40) | (−1,25) | −1,96 |
| 28 | (5.47/34.8) | 5.59 35 | (1,09) | (−1,43) | (−1,32) | −2,05 | |||
| 10 | LMNB1 | P20700 | Lamin‐B1 | 5.11/66.4 (5.11/65.9) | 5.11 66 | (−1,01) | (−1,36) | (−1,13) | −1,53 |
| 17 | LUM | P51884 | Lumican | 6.16/38.4 | 4.45 53 | (−1,21) | (1,48) | 2,81 | 5,02 |
| 18 | (6.17/36.7) | 4.51 53 | (−1,24) | (1,52) | (2,38) | 4,52 | |||
| 19 | 4.61 53 | (−1,29) | (2,22) | (2,65) | 7,59 | ||||
| 20 | 4.71 52 | (−1,01) | (2,34) | (2,25) | 5,23 | ||||
| 36 | TPM1 | P09493 | Tropomyosin α‐1 chain (isoform 8) | 4.71/32.8 | 4.71 33 | (−1,06) | (1,36) | 2,10 | 3,03 |
| 37 | isoform 1 or 9 | 4.69/32.71 | 4.69 33 | (−1,09) | (1,32) | (2,01) | 2,90 | ||
| 35 | TPM2 | P07951 | Tropomyosin β chain (isoform 2) | 4.63/32.9 | 4.62 35 | (−1,04) | (1,54) | 2,45 | 3,91 |
| 8 | VPS35 | Q96QK1 | Vacuolar protein sorting‐associated protein 35 | 5.32/91.7 | 5.36 82 | (−1,02) | (−1,91) | (−1,60) | −2,99 |
| 9 | 5.41 82 | (1,02) | (−1,54) | (−1,38) | −2,17 | ||||
| 12 | WARS | P23381 | Tryptophan‐tRNA ligase (isoform 1 or 2) | 5.83/53.21 (5.83/53.01) | 5.83 55 | (1,09) | (−1,45) | (−1,42) | −2,29 |
Spot numbers are according to Fig. S1. Descriptions and UniProt accession numbers for the identified spots are shown. Spots belonging to the same protein are clustered. Protein fragments are indicated with asterisks. Specific protein isoforms were validated according to spot positions in the gel and the covered protein sequence as well as isoform‐specific peptides obtained by mass spectrometry. Theoretical spot identifications were calculated according to full or mature (in parentheses) protein sequences, whereas detected spot positions in the gel were determined according to selected marker spots. If the identified spot allowed for the presence of several isoforms, theoretical values were indicated for the most common isoform 1 or A. Ratio shows the change in mean normalized spot volumes between elective (E) and spontaneous (S) term birth or between basal (Ba) and chorionic (Ch) plates of the placenta. Changes with a too‐low ratio (<1.5‐fold) or no significance (P > 0.05) are denoted by parentheses. Only the amount of one protein (ACTB) changed significantly in both comparisons (E versus S and Ba versus Ch). For more details about protein levels, statistical significance and protein identification, see Tables S1 and S2.
Figure 1Proteomic changes between elective (E) and spontaneous (S) term birth in basal (Ba) and chorionic (Ch) plates of the placenta. Sections of the gel represent the exact spot positions and expression profiles of the protein level according to the mean normalized spot volumes for the spots shown in Fig. S1. Spots corresponding to the same protein are clustered with a vertical line. Protein fragments are indicated with asterisks. Statistically significant changes (P < 0.05) in expression profiles are shown by horizontal brackets. In the comparisons, six placenta samples were included per group.
Figure 2Proteomic changes between basal (Ba) and chorionic (Ch) plates of the placenta. Samples were collected after elective (E) or spontaneous (S) term birth. Gel parts represent the exact spot positions and expression profiles of the protein level according to the mean normalized spot volumes for the spots shown in Fig. S1. For spots 17–20, the exact positions are shown in gel parts representative of the chorionic plate. Spots corresponding to the same protein are clustered with a vertical line. Protein fragments are indicated with asterisks. Statistically significant changes (P < 0.05) in expression profiles are shown by horizontal brackets. In the comparisons, six placenta samples were included per group.
Figure 3Placental localization of CPPED1 in spontaneous and elective births. Immunostaining of CPPED1 in full‐term placentas from spontaneous (n = 6) or elective births (n = 6). Representative placentas immunostained with anti‐human CPPED1 antibodies. Immunostaining is indicated by filled large arrows in cytotrophoblasts, unfilled large arrows in syncytiotrophoblasts, filled small arrows in endothelium, unfilled arrowheads in leucocytes and filled arrowheads in decidual trophoblasts. Original magnification is 20× in all figures. Control represents isotype controls for immunostaining. Scale bar, 100 μm.
Figure 4The mRNA levels of in spontaneous and elective term placentas. Relative mRNA levels from the basal or chorionic plates were normalized to mRNA levels of the housekeeping gene . Differences were analysed with non‐parametric Mann–Whitney U‐test. Statistically significant changes according to the non‐parametric Mann–Whitney U‐test are indicated by one (P < 0.05) and four (P < 0.0001) asterisks. Solid lines denote median values.
Figure 5Phosphorylation of AKT1 and FOXO1 in spontaneous and elective births. The phosphorylation at Ser473 of AKT1 (pAKT1) was quantitated and compared to total AKT1 (spontaneous term birth n = 18, elective term birth n = 13) (A) and phosphorylation at Ser256 of FOXO1 (pFOXO1) was quantitated and compared to total FOXO1 (spontaneous term birth n = 16, elective term birth n = 12) (B) by Western blotting. NS means not significant change according to Mann–Whitney U‐test. Solid lines denote median values.
Figure 6Placental localization of phosphorylated FOXO1 and phosphorylated FOXO3 in spontaneous and elective births. Immunostaining of phosphorylated FOXO1 (A) and phosphorylated FOXO3 (B) in full‐term placentas after spontaneous and elective delivery. Immunostaining is indicated by filled large arrows in cytotrophoblasts, unfilled large arrows in syncytiotrophoblasts and filled arrowheads in decidual trophoblasts. Original magnification is 40× in samples and 20× in controls. Controls represent isotype controls for immunostaining. Scale bars, 16 μm and 25 μm for samples and controls, respectively.